Biopharmaceutical company GSK plc (LSE/NYSE:GSK) on Wednesday reported positive news regarding the ongoing Zantac (ranitidine) litigation.

The Delaware Supreme Court has agreed to review a lower court's decision allowing the introduction of plaintiffs' expert evidence. This is a significant development, as interlocutory reviews are granted in exceptional circumstances.

The company maintains that the scientific consensus remains clear: there is no consistent or reliable evidence linking ranitidine to an increased risk of cancer. Numerous epidemiological studies support this position, including data from over 1 million patients.

GSK said that it is committed to defending itself vigorously and managing this litigation in the best interests of the company and its shareholders. The Delaware litigation will proceed alongside the Supreme Court review, and GSK will continue to press additional defences, such as requiring plaintiffs to prove both ranitidine use and a diagnosis.